rxdav post from a few months ago.........16 Feb 2022 17:51
........"I think the majority can agree that things with regard to LFT don't seem to have worked out how we would all have liked (bit of an understatement I know) - we don't know all the reasons and might never. It's a depressing situation when so much was promised, likely naively, by Dr. Smith - but who could have possibly foreseen the incompetence and corruption that is the sad hallmark our abysmal government?
However, having said that, we really have to move on (there is no option) - hope that the LFT does indeed (if somewhat belatedly (another understatement)) come good and, critically, that AVA progresses as scheduled.
What would help immeasurably at this time of uncertainty is some communication from AVCT - and given Dr. Smith's previous enthusiasm to appear on video (when things looked on the up) - I don't think that's too much to ask?
All IMHO of course."
Are you suggesting Dr Smith was led astray by a corrupt government rxdav? That's wild and reckless speculation on your part rxdav.
Their is demonstrable proof that NCYT, ODX and ABDX were led up the garden path. The services and products they provided have still yet to be paid for. No such claim can be made for AVCT though. Your darling Alastair has more likely spent years hiding behind a NDA that may or may not even exist to save telling investors that Avacta's test is not the gold standard LFT he made it out to be when he was craving his £50m and funds for the mortgage on a shiny new mansion.
Manufacturing this test design has been next to impossible for every manufacturer he's taken the test to, and when it was finally made after months of painstaking effort by Abingdon, it turns out Avacta's design is not capable of picking up new variants adequately.
The government can be blamed for a lot, but they can't be blamed for Avacta's failings. As Dr Bell said, some British LFT designers need to try harder, and Avacta is one of them. Given the noises that were coming from the government in the summer of 2020, it was obvious they were giving Avacta every chance to produce an effective LFT, and in the end, Avacta and Alastair failed to produce the goods.
The amount of work the manufacturers like Abingdon have had to put into getting Avacta's test to TT shows how poorly designed the test was to begin with. ABDX probably have a better claim to the IP than AVCT at this point, especially when AVCT let slip they were using generic antibodies in their test.